Notable Calls
RSS feedNotablecalls@gmail.com
Thursday, June 29, 2006
Calls of Note Part 1
- Piper Jaffray comments on Autodesk (NASDAQ:ADSK) saying their early round checks with 12 major Autodesk resellers (9 U.S., 3 Europe) indicate that, with 1 month left in the quarter, Q2 is tracking to be primarily in line with consensus ($0.35 on $446.9m). From a quota perspective, on average, the resellers in our sample expect to finish Q2 at 100% of quota. Based on our previous checks, see table below, 100% of quota from this sample of VARs would suggest a range of in line to 1% revenue upside for the quarter. Maintains Outperform and $47 tgt.
Notablecalls: Note that on June 21 Piper was out with a call on ADSK suggesting the co may be in trouble. The stock is down ~10% since then. I would not be surprised to see a small bounce in the coming days. I would not hold the stock below recent lows, though.
- Merrill Lynch comments on Alexion Pharma (NASDAQ:ALXN) after the co officially discontinued development of pipeline drug pexelizumab yesterday. Merrill notes the value of this drug had been removed from the stock following its most recent failure in November '05, followed by guidance from the company that it would discontinue the study and program, so this news should not impact the stock and does not change valuation.
The primary focus for Alexion remains filing its BLA for Soliris for paroxysmal nocturnal hemoglobinuria (PNH) and continuing pre-marketing educational programs for hematologists to help identify patients ahead of launch. Maintains Buy rating.
Notablecalls: Not actionable but good to know category. Note ALXN traded down as much as 5 pts in after market trading.
- Morgan Stanley reits their Overweight rating on VeriSign (NASDAQ:VRSN) as we head into the back half of 2006 - a seasonally brighter period for the company. Quite simply, in such a challenging time, the visibility and deep-seated position of VeriSign's model makes this a must own name in firm's view. With this quarter its last one facing difficult compares over the lofty Jamba! numbers of last year, VeriSign has positioned its business to take advantage of some of the better security and Internet commerce growth trends in the market.
Notablecalls: Not actionable but good to know category.
Notablecalls: Note that on June 21 Piper was out with a call on ADSK suggesting the co may be in trouble. The stock is down ~10% since then. I would not be surprised to see a small bounce in the coming days. I would not hold the stock below recent lows, though.
- Merrill Lynch comments on Alexion Pharma (NASDAQ:ALXN) after the co officially discontinued development of pipeline drug pexelizumab yesterday. Merrill notes the value of this drug had been removed from the stock following its most recent failure in November '05, followed by guidance from the company that it would discontinue the study and program, so this news should not impact the stock and does not change valuation.
The primary focus for Alexion remains filing its BLA for Soliris for paroxysmal nocturnal hemoglobinuria (PNH) and continuing pre-marketing educational programs for hematologists to help identify patients ahead of launch. Maintains Buy rating.
Notablecalls: Not actionable but good to know category. Note ALXN traded down as much as 5 pts in after market trading.
- Morgan Stanley reits their Overweight rating on VeriSign (NASDAQ:VRSN) as we head into the back half of 2006 - a seasonally brighter period for the company. Quite simply, in such a challenging time, the visibility and deep-seated position of VeriSign's model makes this a must own name in firm's view. With this quarter its last one facing difficult compares over the lofty Jamba! numbers of last year, VeriSign has positioned its business to take advantage of some of the better security and Internet commerce growth trends in the market.
Notablecalls: Not actionable but good to know category.
posted by notablecalls # 4:11 AM 
Archives
June 2006 July 2006 August 2006 September 2006 October 2006 November 2006 December 2006 January 2007 February 2007 March 2007 April 2007 May 2007 June 2007 July 2007 August 2007 September 2007 October 2007 November 2007 December 2007 January 2008 February 2008 March 2008 April 2008 May 2008 June 2008 July 2008 August 2008
